282 related articles for article (PubMed ID: 15045937)
1. [Diagnosis and treatment for adrenocortical carcinoma].
Iihara M; Obara T
Gan To Kagaku Ryoho; 2004 Mar; 31(3):342-5. PubMed ID: 15045937
[TBL] [Abstract][Full Text] [Related]
2. Mitotane associated with cisplatin, etoposide, and doxorubicin in advanced childhood adrenocortical carcinoma: mitotane monitoring and tumor regression.
Zancanella P; Pianovski MA; Oliveira BH; Ferman S; Piovezan GC; Lichtvan LL; Voss SZ; Stinghen ST; Callefe LG; Parise GA; Santana MH; Figueiredo BC
J Pediatr Hematol Oncol; 2006 Aug; 28(8):513-24. PubMed ID: 16912591
[TBL] [Abstract][Full Text] [Related]
3. Adrenocortical carcinoma.
van Ditzhuijsen CI; van de Weijer R; Haak HR
Neth J Med; 2007 Feb; 65(2):55-60. PubMed ID: 17379929
[TBL] [Abstract][Full Text] [Related]
4. Update in adrenocortical carcinoma.
Fassnacht M; Kroiss M; Allolio B
J Clin Endocrinol Metab; 2013 Dec; 98(12):4551-64. PubMed ID: 24081734
[TBL] [Abstract][Full Text] [Related]
5. A phase II trial of combination chemotherapy and surgical resection for the treatment of metastatic adrenocortical carcinoma: continuous infusion doxorubicin, vincristine, and etoposide with daily mitotane as a P-glycoprotein antagonist.
Abraham J; Bakke S; Rutt A; Meadows B; Merino M; Alexander R; Schrump D; Bartlett D; Choyke P; Robey R; Hung E; Steinberg SM; Bates S; Fojo T
Cancer; 2002 May; 94(9):2333-43. PubMed ID: 12015757
[TBL] [Abstract][Full Text] [Related]
6. Mitotane associated with etoposide, doxorubicin, and cisplatin in the treatment of advanced adrenocortical carcinoma. Italian Group for the Study of Adrenal Cancer.
Berruti A; Terzolo M; Pia A; Angeli A; Dogliotti L
Cancer; 1998 Nov; 83(10):2194-200. PubMed ID: 9827725
[TBL] [Abstract][Full Text] [Related]
7. [A case of adrenal cortical carcinoma].
Oida T; Souma T; Doi H; Hida S; Takasu K
Hinyokika Kiyo; 2002 Nov; 48(11):667-70. PubMed ID: 12512139
[TBL] [Abstract][Full Text] [Related]
8. [A Case of Adrenocortical Carcinoma Successfully Treated with Multimodal Therapy].
Bando S; Ishii G; Yamada H; Kimura T; Furuta N; Egawa S
Hinyokika Kiyo; 2016 Jan; 62(1):15-9. PubMed ID: 26932330
[TBL] [Abstract][Full Text] [Related]
9. [Adrenocortical carcinoma and its treatment].
Tupikowski W; Bednarek-Tupikowska G; Florczak A
Postepy Hig Med Dosw (Online); 2004 Feb; 58():27-36. PubMed ID: 15069374
[TBL] [Abstract][Full Text] [Related]
10. Adjuvant mitotane in adrenocortical carcinoma.
Machens A; Dralle H
N Engl J Med; 2007 Sep; 357(12):1258-9; author reply 1259. PubMed ID: 17891837
[No Abstract] [Full Text] [Related]
11. [Therapy of the adrenocortical carcinoma with Lysodren (o,p'-DDD). Therapeutic management by monitoring o,p'-DDD blood levels].
Heilmann P; Wagner P; Nawroth PP; Ziegler R
Med Klin (Munich); 2001 Jul; 96(7):371-7. PubMed ID: 11494911
[TBL] [Abstract][Full Text] [Related]
12. Liposomal polychemotherapy improves adrenocortical carcinoma treatment in a preclinical rodent model.
Hantel C; Jung S; Mussack T; Reincke M; Beuschlein F
Endocr Relat Cancer; 2014 Jun; 21(3):383-94. PubMed ID: 24532475
[TBL] [Abstract][Full Text] [Related]
13. Oncocytic adrenocortical carcinoma.
Tanaka K; Kumano Y; Kanomata N; Takeda M; Hara I; Fujisawa M; Kawabata G; Kamidono S
Urology; 2004 Aug; 64(2):376-7. PubMed ID: 15302503
[TBL] [Abstract][Full Text] [Related]
14. Phase II evaluation of cisplatin and etoposide followed by mitotane at disease progression in patients with locally advanced or metastatic adrenocortical carcinoma: a Southwest Oncology Group Study.
Williamson SK; Lew D; Miller GJ; Balcerzak SP; Baker LH; Crawford ED
Cancer; 2000 Mar; 88(5):1159-65. PubMed ID: 10699907
[TBL] [Abstract][Full Text] [Related]
15. Metastatic adrenocortical carcinoma with a prolonged response to mitotane.
Pal SK; Gartrell B; Olsson CA; Stein CA
Oncology (Williston Park); 2014 Jul; 28(7):624-5, 642. PubMed ID: 25144285
[No Abstract] [Full Text] [Related]
16. Tailored hormonal therapy in secretory adrenocortical cancer.
Carmona-Bayonas A; Soler IO; Gómez FI; Billalabeitia EG; Saura HP; Tafalla MS; Díaz MP
Ann Oncol; 2007 Jul; 18(7):1281. PubMed ID: 17675396
[No Abstract] [Full Text] [Related]
17. Use of a levonorgestrel-releasing intrauterine device for menorrhagia treatment during adjuvant therapy of adrenocortical carcinoma with mitotane.
Szkodziak PR; Czuczwar P; Woźniak S; Szkodziak F; Paszkowski T
Ginekol Pol; 2017; 88(10):576-577. PubMed ID: 29192420
[TBL] [Abstract][Full Text] [Related]
18. Metastatic adrenocortical carcinoma presenting simultaneously with Cushing's and Conn's syndromes: a case report.
Beom SH; Lee KW; Yang Y; Choi Y; Song KH; Kim YJ; Kim JH; Bang SM; Chung JH; Lee JS
Jpn J Clin Oncol; 2011 Nov; 41(11):1287-91. PubMed ID: 21980052
[TBL] [Abstract][Full Text] [Related]
19. [A Case Report of a Patient with Metastatic Adrenocortical Carcinoma who Received the Combination Etoposide, Doxorubicin, Cisplatin, and Mitotane Therapy and Achieved Remission].
Ueda S; Nakane K; Namiki S; Takeuchi Y; Kawase M; Takeuchi S; Kawase K; Nakai C; Kato D; Takai M; Iinuma K; Tsuchiya T; Miyazaki T; Koie T
Hinyokika Kiyo; 2022 May; 68(5):139-143. PubMed ID: 35748231
[TBL] [Abstract][Full Text] [Related]
20. Mitotane With or Without Cisplatin and Etoposide for Patients with a High Risk of Recurrence in Stages 1-3 Adrenocortical Cancer After Surgery.
Sarvestani AL; Gregory SN; Teke ME; Terzolo M; Berruti A; Hernandez JM; Habra MA
Ann Surg Oncol; 2023 Feb; 30(2):680-682. PubMed ID: 36305989
[No Abstract] [Full Text] [Related]
[Next] [New Search]
